Navidea, FDA settle on details for NAV5001 trials

08/22/2013 | AuntMinnie.com (free registration)

Navidea Biopharmaceuticals has reached an agreement with the FDA regarding special-protocol assessments for Phase III trials for Navidea's investigational imaging agent NAV5001. The agent targets the brain's dopamine transporters for distinguishing Parkinsonian syndromes with SPECT imaging. Navidea plans to begin the trials this year.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN